Pieris Pharmaceuticals, INC

Palvella Therapeutics announced strong Q2 2026 financial results, highlighting significant progress in its QTORIN rapamycin NDA submission for microcystic lymphatic malformations and advancement of other pipeline programs.

Palvella Therapeutics, Inc. shared a corporate presentation on July 14, 2026, detailing advancements in its QTORIN platform and pipeline for rare skin diseases.

Palvella Therapeutics, Inc. has appointed Matthew Pauls to its Board of Directors, expanding the board to eight members.

Palvella Therapeutics stockholders approved an increase in equity incentive plan shares and ratified director elections at the 2026 Annual Meeting.

Palvella Therapeutics announced positive clinical data from Phase 3 SELVA and Phase 2 TOIVA studies for QTORIN rapamycin at the ISSVA World Congress 2026, supporting its potential as a first-in-disease therapy for rare vascular malformations.

Palvella Therapeutics announced new data from its Phase 2 TOIVA trial of QTORIN rapamycin for cutaneous venous malformations, showing significant improvement in bleeding and high patient satisfaction.

Palvella Therapeutics reports substantial progress in its QTORIN rapamycin development for rare skin diseases, with an NDA submission on track for H2 2026 and a potential 2027 U.S. launch, alongside increased R&D spending.

Palvella Therapeutics reports a significant increase in R&D expenses for Q1 2026, alongside a substantial cash infusion from a recent equity financing.

Palvella Therapeutics, a clinical-stage biopharmaceutical company, reported increased net losses and cash burn in Q3 2025, while successfully completing enrollment for two key clinical trials and expanding its QTORIN rapamycin development program.

Palvella Therapeutics, a clinical-stage biopharmaceutical company, reported increased operating losses in Q2 2025 but maintains sufficient cash to fund operations into the second half of 2027, driven by ongoing clinical trials for rare skin diseases.

Palvella Therapeutics reports a net loss of $8.2 million for Q1 2025, focusing on the clinical development of QTORIN rapamycin for rare genetic skin diseases.

Pieris Pharmaceuticals is set to merge with Palvella Therapeutics, marking a significant strategic shift following a period of restructuring and discontinued research programs.

Palvella Therapeutics announced positive Phase 3 clinical trial results for QTORIN rapamycin in microcystic lymphatic malformations and secured $215.8 million in a public offering, despite ongoing operating losses.

Palvella Therapeutics (PVLA) shifts focus to rare genetic skin diseases following a reverse merger, advancing QTORIN rapamycin clinical trials.

Pieris Pharmaceuticals has filed an amendment to its annual report on Form 10-K, primarily to include previously omitted information regarding executive compensation, corporate governance, and related matters.

Pieris Pharmaceuticals will discontinue research and development, reduce its workforce, and focus on partnered immuno-oncology assets to extend its cash runway into 2027.

Kathleen Goin, Chief Operating Officer of Pieris Pharmaceuticals, Inc., sold 4,302 shares of common stock on July 15, 2026.

Palvella Therapeutics, Inc. reports that Director Matthew Pauls acquired 6,000 stock options with an exercise price of $154.84.

Matthew E. Korenberg, CFO and Treasurer of Paltella Therapeutics, Inc., reported the acquisition of 1,000 shares of common stock via the exercise of stock options.

Director Christopher P. Kiritsy was granted 3,000 stock options in Palvella Therapeutics, Inc. on June 10, 2026.

Director George M. Jenkins was granted 3,000 stock options in Palvella Therapeutics, Inc. as part of a standard equity incentive.

Director John Doux was granted 3,000 stock options in Palvella Therapeutics, Inc. as part of standard equity compensation.

Palvella Therapeutics has issued its 2026 proxy statement detailing director elections, executive compensation, and a proposal to increase equity incentive plan shares.

Palvella Therapeutics will hold its annual stockholder meeting virtually on June 10, 2025, to vote on director elections, auditor ratification, and executive compensation.

Palvella Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, focusing on director elections, auditor ratification, and executive compensation.

Pieris Pharmaceuticals will hold its 2024 annual meeting of stockholders virtually on December 2, 2024, to vote on director elections, auditor ratification, executive compensation, and other business.

Palvella Therapeutics files an amendment to its registration statement for the potential resale of up to 5,634,504 shares of its common stock by selling stockholders.

Palvella Therapeutics, Inc. has filed a registration statement for the resale of up to 5.6 million shares of its common stock following its recent merger with Pieris Pharmaceuticals.

Prudential Financial, Inc. has filed a Schedule 13G, reporting a 6.7% beneficial ownership in Palvella Therapeutics, Inc.

Jennison Associates LLC has reported beneficial ownership of 960,619 shares, representing 6.7% of Palvella Therapeutics Inc.'s common stock, as of June 30, 2026.

Frazier Life Sciences funds updated their beneficial ownership in Palvella Therapeutics, Inc., reporting a 6.0% stake for its Public Fund.

Biotechnology Value Fund and its affiliates have disclosed a combined beneficial ownership of 9.99% in Palvella Therapeutics, Inc., including shares from pre-funded warrants.

Suvretta Capital Management, LLC and Averill Master Fund, Ltd. updated their beneficial ownership in Palvella Therapeutics, Inc., reporting 7.4% and 6.5% stakes respectively.

Samsara BioCapital, L.P. and its affiliates reported a reduced beneficial ownership of 3.1% in Palvella Therapeutics, Inc. common stock as of June 30, 2025.